Related Experiment Video
Updated: Feb 4, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Biomaterials for vaccine-based cancer immunotherapy
Rui Zhang1, Margaret M Billingsley1, Michael J Mitchell2
1Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, United States.
Abstract:
The development of therapeutic cancer vaccines as a means to generate immune reactivity against tumors has been explored since the early discovery of tumor-specific antigens by Georg Klein in the 1960s. However, challenges including weak immunogenicity, systemic toxicity, and off-target effects of cancer vaccines remain as barriers to their broad clinical translation. Advances in the design and implementation of biomaterials are now enabling enhanced efficacy and reduced toxicity of cancer vaccines by controlling the presentation and release of vaccine components to immune cells and their microenvironment. Here, we discuss the rational design and clinical status of several classes of cancer vaccines (including DNA, mRNA, peptide/protein, and cell-based vaccines) along with novel biomaterial-based delivery technologies that improve their safety and efficacy. Further, strategies for designing new platforms for personalized cancer vaccines are also considered.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations
Tumor Immunotherapy
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Prevention
Some...

